

Cost-effectiveness analysis of use of a polypill versus usual care or best practice for primary prevention in people at high risk of cardiovascular disease

Jowett, Sue; Barton, Pelham; Roalfe, Andrea; Fletcher, Kate; Hobbs, F D Richard; McManus, Richard; Mant, Jonathan

DOI:
[10.1371/journal.pone.0182625](https://doi.org/10.1371/journal.pone.0182625)

License:
Creative Commons: Attribution (CC BY)

Document Version
Peer reviewed version

Citation for published version (Harvard):
Jowett, S, Barton, P, Roalfe, A, Fletcher, K, Hobbs, FDR, McManus, R & Mant, J 2017, 'Cost-effectiveness analysis of use of a polypill versus usual care or best practice for primary prevention in people at high risk of cardiovascular disease', *PLoS ONE*. <https://doi.org/10.1371/journal.pone.0182625>

[Link to publication on Research at Birmingham portal](#)

Publisher Rights Statement:

Jowett S, Barton P, Roalfe A, Fletcher K, Hobbs FDR, McManus RJ, et al. (2017) Cost-effectiveness analysis of use of a polypill versus usual care or best practice for primary prevention in people at high risk of cardiovascular disease. *PLoS ONE* 12(9): e0182625. <https://doi.org/10.1371/journal.pone.0182625>

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

S1 supplementary Table A Baseline patient sub-group characteristics by age, sex and guideline category

Men, age-group (mean age) [BP in mmHg]	Mean (SD) 10 year CV risk (%)	Mean (SD) Systolic BP [BP in mmHg]	Mean (SD) no. AHT drugs	Proportion at baseline (%)
40-49 (45.0) n=273				
On statins, <=140 SBP	8.4 (4.9)	125.6 (10.1)	-	15.4
On statins, >140 SBP	12.1 (6.4)	151.6 (15.2)	-	3.3
On statins & AHT, <=140 SBP	7.0 (3.2)	128.2 (10.2)	1.78 (0.70)	14.7
On statins & AHT, >140 SBP	12.4 (9.5)	150.7 (12.2)	1.55 (0.83)	10.6
On AHT, <=140 SBP, 10y CVD <20%	8.5 (3.6)	131.4 (7.6)	1.62 (0.74)	33.3
On AHT, <=140 SBP, 10y CVD 20%+	23.6 (1.0)	139.5 (0.7)	1.50 (0.81)	0.7
On AHT, >140 SBP, 10y CVD <20%	11.7 (3.9)	153.1 (11.1)	1.58 (0.69)	19.4
On AHT, >140 SBP, 10y CVD 20%+	24.0 (4.8)	168.6 (17.1)	2.14 (0.69)	2.6
50-59 (54.5), n=481				
On statins, <=140 SBP	14.3 (7.1)	127.6 (9.8)	-	12.3
On statins, >140 SBP	22.1 (7.7)	149.1 (6.3)	-	3.9
On statins & AHT, <=140 SBP	12.9 (6.4)	128.3 (8.9)	1.72 (0.78)	20.8
On statins & AHT, >140 SBP	19.8 (7.1)	151.1 (10.5)	1.95 (0.85)	12.1
On AHT, <=140 SBP, 10y CVD <20%	12.5 (3.6)	130.0 (7.9)	1.63 (0.72)	26.8
On AHT, <=140 SBP, 10y CVD 20%+	24.2 (4.5)	132.2 (6.5)	1.56 (0.51)	5.2
On AHT, >140 SBP, 10y CVD <20%	15.1 (2.8)	149.3 (16.3)	1.63 (0.80)	11.6
On AHT, >140 SBP, 10y CVD 20%+	25.3 (5.3)	157.8 (14.3)	1.66 (0.73)	7.3
Men, age-group (mean age)	Mean 10 year CV risk (%)	Mean (SD) Systolic BP	Mean (SD) no. AHT drugs	Proportion at baseline (%)
60-69 (64.2), n=653				

On statins, <=140 SBP	20.5 (8.7)	128.9 (10.7)	-	12.4
On statins, >140 SBP	25.8 (8.5)	152.0 (9.1)	-	4.4
On statins & AHT, <=140 SBP	19.1 (6.4)	130.7 (8.1)	1.81 (0.79)	22.2
On statins & AHT, >140 SBP	26.5 (9.0)	151.8 (12.3)	1.77 (0.72)	16.1
On AHT, <=140 SBP, 10y CVD <20%	15.8 (3.2)	130.2 (9.3)	1.65 (0.74)	12.9
On AHT, <=140 SBP, 10y CVD 20%+	25.5 (5.1)	133.1 (7.4)	1.58 (0.65)	11.0
On AHT, >140 SBP, 10y CVD <20%	1.7 (1.9)	145.3 (2.9)	1.83 (0.76)	4.5
On AHT, >140 SBP, 10y CVD 20%+	29.1 (6.3)	153.4 (10.1)	1.8 (0.86)	16.5
70-74 (71.8), n=266				
On statins, <=140 SBP	24.5 (7.1)	129.5 (9.3)	-	8.7
On statins, >140 SBP	26.7 (3.4)	148.0 (6.3)	-	3.0
On statins & AHT, <=140 SBP	23.5 (5.5)	130.0 (8.2)	1.90 (0.74)	18.8
On statins & AHT, >140 SBP	30.2 (8.2)	150.3 (8.9)	1.69 (0.75)	24.4
On AHT, <=140 SBP, 10y CVD <20%	17.3 (2.1)	122.3 (12.1)	1.82 (0.87)	4.1
On AHT, <=140 SBP, 10y CVD 20%+	26.3 (5.7)	132.4 (6.4)	1.63 (0.73)	20.3
On AHT, >140 SBP, 10y CVD <20%	-	-	-	0
On AHT, >140 SBP, 10y CVD 20%+	31.2 (6.2)	149.6 (8.1)	1.69 (0.79)	20.7

Men, age-group (mean age)	Mean 10 year CV risk (%)	Mean (SD) Systolic BP	Mean (SD) no. AHT drugs	Proportion at baseline (%)
75+ (80.3), n=126				
On statins, <=140 SBP	23.4 (3.1)	126.7 (12.8)	-	1.8
On statins, >140 SBP	33.2 (9.7)	151.7 (8.9)	-	2.9
On statins & AHT, <=140 SBP	25.5 (6.9)	127.1 (10.3)	1.59 (0.74)	15.7
On statins & AHT, >140 SBP	34.8 (5.8)	153.1 (11.3)	2.00 (0.77)	12.2
On AHT, <=140 SBP, 10y CVD <20%	18.7 (0.4)	120.5 (27.6)	3.00 (0.00)	0.6
On AHT, <=140 SBP, 10y CVD 20%+	31.3 (6.6)	131.1 (8.8)	1.77 (0.79)	30.2
On AHT, >140 SBP, 10y CVD <20%	-	-	-	0
On AHT, >140 SBP, 10y CVD 20%+	39.1 (7.8)	152.5 (11.9)	1.68 (0.72)	36.6

SBP: Systolic Blood Pressure; AHT: Anti-Hypertensive Treatment; CV: Cardiovascular; CVD: Cardiovascular Disease

Women, age-group (mean age)	Mean (SD) 10 year CV risk	Mean (SD) Systolic BP	Mean (SD) no. AHT drugs	Proportion at baseline (%)
40-49 (45.6), n=223				
On statins, <=140 SBP	4.8 (2.8)	122.1 (11.2)	-	11.7
On statins, >140 SBP	4.6 (2.2)	151.0 (9.5)	-	1.3
On statins & AHT, <=140 SBP	4.6 (3.2)	123.9 (10.4)	1.56 (0.96)	7.2
On statins & AHT, >140 SBP	5.8 (2.3)	150.4 (6.9)	1.60 (0.55)	2.2
On AHT, <=140 SBP, 10y CVD <20%	4.4 (2.7)	126.7 (10.2)	1.34 (0.56)	53.4
On AHT, <=140 SBP, 10y CVD 20%+	-	-	-	0
On AHT, >140 SBP, 10y CVD <20%	8.4 (4.4)	154.4 (13.7)	1.54 (0.73)	23.3
On AHT, >140 SBP, 10y CVD 20%+	23.7 (4.3)	153.0 (15.6)	1.00 (0.00)	0.9
50-59 (55.1), n=463				
On statins, <=140 SBP	8.1 (4.1)	125.8 (9.5)	-	13.0
On statins, >140 SBP	12.8 (6.4)	149.4 (7.7)	-	3.5
On statins & AHT, <=140 SBP	7.9 (3.9)	128.3 (9.2)	1.58 (0.59)	17.9
On statins & AHT, >140 SBP	10.9 (4.7)	152.1 (11.8)	1.68 (0.65)	8.9
On AHT, <=140 SBP, 10y CVD <20%	7.4 (3.3)	128.0 (9.4)	1.59 (0.68)	33.9
On AHT, <=140 SBP, 10y CVD 20%+	23.4 (2.2)	140.0 (0.0)	1.00 (0.00)	0.4
On AHT, >140 SBP, 10y CVD <20%	11.2 (3.8)	152.2 (10.8)	1.56 (0.67)	19.4
On AHT, >140 SBP, 10y CVD 20%+	25.2 (3.6)	167.7 (12.7)	1.71 (0.83)	3.0

Women, age-group (mean age)	Mean (SD) 10 year CV risk	Mean (SD) Systolic BP	Mean (SD) no. AHT drugs	Proportion at baseline (%)
60-69 (64.4), n=733				
On statins, <=140 SBP	9.7 (4.7)	127.9 (10.6)	-	9.7
On statins, >140 SBP	15.3 (5.7)	151.7 (12.1)	-	4.8
On statins & AHT, <=140 SBP	11.1 (4.5)	129.1 (9.1)	1.67 (0.75)	21.2
On statins & AHT, >140 SBP	15.9 (7.0)	152.1 (10.9)	1.70 (0.82)	15.4
On AHT, <=140 SBP, 10y CVD <20%	10.9 (3.7)	129.2 (10.4)	1.71 (0.73)	28.9
On AHT, <=140 SBP, 10y CVD 20%+	23.1 (3.0)	136.9 (2.9)	1.92 (0.79)	1.6
On AHT, >140 SBP, 10y CVD <20%	14.0 (2.9)	149.9 (8.1)	1.70 (0.72)	13.8
On AHT, >140 SBP, 10y CVD 20%+	23.7 (3.3)	158.9 (16.9)	1.65 (0.81)	4.6
70-74 (71.9), n=353				
On statins, <=140 SBP	13.0 (3.9)	129.0 (9.1)	-	6.0
On statins, >140 SBP	24.8 (8.1)	157.3 (13.1)	-	4.8
On statins & AHT, <=140 SBP	13.1 (4.4)	131.6 (8.1)	1.99 (0.84)	21.8
On statins & AHT, >140 SBP	19.1 (6.5)	149.9 (7.9)	1.81 (0.76)	17.8
On AHT, <=140 SBP, 10y CVD <20%	13.7 (3.6)	131.4 (8.8)	1.76 (0.74)	20.4
On AHT, <=140 SBP, 10y CVD 20%+	24.3 (2.7)	132.6 (4.5)	1.71 (0.76)	2.0
On AHT, >140 SBP, 10y CVD <20%	16.5 (2.6)	146.6 (4.1)	1.69 (0.74)	17.3
On AHT, >140 SBP, 10y CVD 20%+	25.0 (5.0)	156.0 (13.4)	1.74 (0.66)	9.9

Women, age-group (mean age)	Mean (SD) 10 year CV risk	Mean (SD) Systolic BP	Mean (SD) no. AHT drugs	Proportion at baseline (%)
75+ (81.2), n=702				
On statins, <=140 SBP	16.0 (7.6)	125.6 (13.0)	-	4.7
On statins, >140 SBP	20.3 (7.3)	153.2 (10.7)	-	3.0
On statins & AHT, <=140 SBP	15.6 (5.2)	130.6 (9.5)	1.90 (0.78)	18.2
On statins & AHT, >140 SBP	22.6 (6.3)	152.7 (11.1)	1.86 (0.72)	16.8
On AHT, <=140 SBP, 10y CVD <20%	16.1 (2.6)	130.2 (8.4)	1.64 (0.74)	15.5
On AHT, <=140 SBP, 10y CVD 20%+	24.2 (3.6)	135.1 (6.2)	1.62 (0.83)	9.7
On AHT, >140 SBP, 10y CVD <20%	17.3 (1.6)	146.2 (3.9)	1.70 (0.69)	5.7
On AHT, >140 SBP, 10y CVD 20%+	27.8 (6.6)	156.7 (14.9)	1.71 (0.77)	26.4

SBP: Systolic Blood Pressure; AHT: Anti-Hypertensive Treatment; CV: Cardiovascular; CVD: Cardiovascular Disease